It's great to see the fundamentals are exciting - I normally...

It's great to see the fundamentals are exciting - I normally just trade using charts, and SRX has one of
the best I've seen in a while.... Here's a copy
of the announcement anyways:

USA running ahead of schedule

SIRTEX MEDICAL LIMITED 2002-08-21 ASX-SIGNAL-G

HOMEX - Sydney

+++++++++++++++++++++++++
SIRTeX Medical Limited is pleased to announce that its USA entry
strategy is progressing ahead of schedule. SIRTeX had a target to
establish 10 treating centres in the USA in the first 12 months of
operation. Since treating its first patient in the USA four months
ago, the company has already trained five centres in the use of
SIR-Spheres(R).

The USA market for the treatment of liver cancer is significant with
over 11,000 cases of primary liver cancer per year and over 57,000
cases of secondary cancer. As SIRTeX Medical's treatment approach is
novel, the ability of the company to develop and penetrate this
market will depend largely on the support it receives from key
opinion leaders. To this end the company is working with leading
cancer centres and the company is extremely pleased with the level of
support its therapy is receiving in the USA market.

In the first month of entering the USA market (May 2002), USA sales
were AUD$25,436 representing a single dose of SIR-Spheres (R). June
sales increased to AUD$70,372 then USA increased further in July to
AUD$303,413. The company expects to invoice over AUD$400,000 of
SIR-Spheres (R) in the USA for the month of August. The revenue base
will expand further in the USA as more centres are established in the
near future.

The USA has already become the company's major source of revenue. The
AUD$303,413 in sales for July from the USA has overtaken the total
revenue from Asia Pacific that was AUD$92,350 for the same period.
This illustrates the importance of the USA market to SIRTeX Medical's
future success and validates management's focus in targeting this
market.

SIRTeX Medical will continue to roll out its technology to high
profile cancer treatment hospitals in the USA. It is expected that
the original first year target of training 10 centres will be
exceeded within the next few months.

EXTENDED INDICATIONS FOR SIR-SPHERES(R)

Currently, SIR-Spheres(R) is indicated for the treatment of secondary
liver cancer derived from the bowel in the USA. The company has an
ongoing program to increase the ways SIR-Spheres(R) can be delivered
and is used to treat a variety of cancers. To this end, company
executives met with the Food and Drug Administration (FDA) on 2
August 2002 to outline its recent phase II trial results. The small
phase II trial showed that median survival of 10 patients treated
with systemic chemotherapy alone was 12.8 months and this was
extended to 27.1 months for the 11 patients treated with systemic
chemotherapy and SIR-Spheres(R). Following that successful meeting, it
was agreed that the company would now submit the results of this
randomised trial to the FDA as a supplemental Pre-Market Approval
(PMA) application. The supplemental application will request
extension of the labelled indications-for-use of its SIR-Spheres(R)
product in the USA to include the use of SIR-Spheres(R) together with
systemic chemotherapy.

SIRTeX Medical has also agreed to work with the FDA to design several
new USA based clinical studies. These new studies will evaluate the
efficacy of SIR-Spheres(R) in primary liver cancer and secondary liver
cancer from neuro-endocrine cancer and pancreas cancer. As all three
groups of patients have been successfully treated in Australia and
Hong Kong, SIRTeX Management is confident that these new studies in
the USA will be successful and will lead to the FDA granting further
extensions to the indications-for-use of the product.

INVESTOR UPDATE

An update on the company will be presented at the AusBiotech 2002
Annual Conference today in Melbourne. A copy of the presentation can
be found on the companys website at www.sirtex.com.

CN Sutton (PhD)
CHIEF EXECUTIVE OFFICER